ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,277.51
      0.80%
      US Tech 100
      18,064.80
      0.02%
      Dow Jones
      38,686.32
      1.51%
      Brent Oil
      81.295
      0.00%
      Bitcoin
      67,685.01
      0.30%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. PDS Biotechnology Corporation (PDSB)

      7. PDS Biotechnology Corporation (PDSB) News

      PDSB

      PDS Biotechnology (PDSB)

      PDS Biotechnology Corporation
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:PDSB
      DateTimeSourceHeadlineSymbolCompany
      05/15/20245:16PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PDSBPDS Biotechnology Corporation
      05/15/20248:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PDSBPDS Biotechnology Corporation
      05/08/20244:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PDSBPDS Biotechnology Corporation
      01/23/20244:33PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PDSBPDS Biotechnology Corporation
      01/23/20244:31PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:PDSBPDS Biotechnology Corporation
      01/22/20245:10PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PDSBPDS Biotechnology Corporation
      01/22/20244:45PMGlobeNewswire Inc.PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical OfficerNASDAQ:PDSBPDS Biotechnology Corporation
      01/16/20248:00AMGlobeNewswire Inc.PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology ConferenceNASDAQ:PDSBPDS Biotechnology Corporation
      12/04/20234:50PMGlobeNewswire Inc.PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:PDSBPDS Biotechnology Corporation
      12/04/20234:02PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PDSBPDS Biotechnology Corporation
      11/28/20237:30AMGlobeNewswire Inc.PDS Biotech Appoints Lars Boesgaard as Chief Financial OfficerNASDAQ:PDSBPDS Biotechnology Corporation
      11/28/20236:02AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PDSBPDS Biotechnology Corporation
      11/14/20237:30AMGlobeNewswire Inc.PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:PDSBPDS Biotechnology Corporation
      11/09/20234:07PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PDSBPDS Biotechnology Corporation
      11/09/20238:00AMGlobeNewswire Inc.PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which Show 75% Survival of ICI Naïve Patients at 36 MonthsNASDAQ:PDSBPDS Biotechnology Corporation
      11/07/20238:00AMGlobeNewswire Inc.PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2023 Financial ResultsNASDAQ:PDSBPDS Biotechnology Corporation
      10/23/20234:06PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PDSBPDS Biotechnology Corporation
      10/23/20238:00AMGlobeNewswire Inc.PDS Biotech Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients at ESMONASDAQ:PDSBPDS Biotechnology Corporation
      10/11/20234:02PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PDSBPDS Biotechnology Corporation
      10/11/20238:00AMGlobeNewswire Inc.PDS Biotech Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate CancerNASDAQ:PDSBPDS Biotechnology Corporation
      10/03/20234:03PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PDSBPDS Biotechnology Corporation
      10/03/20234:03PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PDSBPDS Biotechnology Corporation
      10/03/20239:02AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PDSBPDS Biotechnology Corporation
      10/03/20237:00AMGlobeNewswire Inc.PDS Biotech Announces Interim 24-Month Survival Rate of 74% in Immune Checkpoint Inhibitor Naïve Head and Neck Cancer Patients Treated with PDS0101 in Combination with KEYTRUDA® (pembrolizumab)NASDAQ:PDSBPDS Biotechnology Corporation
      10/02/20234:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PDSBPDS Biotechnology Corporation
      10/02/20238:00AMGlobeNewswire Inc.PDS Biotech Announces PDS0101 Combined with Chemoradiotherapy Associated with Rapid Decline in Circulating Tumor DNA (ctDNA/cfDNA)NASDAQ:PDSBPDS Biotechnology Corporation
      09/26/20238:00AMGlobeNewswire Inc.PDS Biotech to Present at the LD Micro Main Event XVINASDAQ:PDSBPDS Biotechnology Corporation
      09/25/20238:00AMGlobeNewswire Inc.PDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101NASDAQ:PDSBPDS Biotechnology Corporation
      09/20/20234:10PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PDSBPDS Biotechnology Corporation
      09/20/20234:05PMGlobeNewswire Inc.PDS Biotech to Participate in the 2023 Cantor Fitzgerald Global Healthcare ConferenceNASDAQ:PDSBPDS Biotechnology Corporation
       Showing the most relevant articles for your search:NASDAQ:PDSB